Patents by Inventor James Bradley Lorens

James Bradley Lorens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-AXL Antagonistic Antibodies
    Publication number: 20230406941
    Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: February 17, 2023
    Publication date: December 21, 2023
    Applicants: BERGEN TEKNOLOGIOVERFØRING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn Hodneland NILSSON, Tone SANDAL
  • Anti-axl antagonistic antibodies
    Patent number: 11732048
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: November 2, 2021
    Date of Patent: August 22, 2023
    Assignees: Bergen Teknologioverføring AS, BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Nilsson, Tone Sandal
  • AXL Inhibitors for Antiviral Therapy
    Publication number: 20230250169
    Abstract: This disclosure relates to compostions and methods for preventing and treating a viral infection in a subject. In particular, the present disclosure provides compostions and methods of preventing or treating infection of a subject with a coronavirus such as the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) that causes the disease COVID-19.
    Type: Application
    Filed: April 1, 2021
    Publication date: August 10, 2023
    Applicant: BERGENBIO ASA
    Inventors: James Bradley LORENS, Wendy MAURY
  • Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus
    Publication number: 20230149397
    Abstract: The present invention concerns an Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.
    Type: Application
    Filed: December 16, 2022
    Publication date: May 18, 2023
    Applicant: BERGENBIO ASA
    Inventors: James Bradley LORENS, Gro GAUSDAL
  • Anti-Axl antagonistic antibodies
    Patent number: 11584796
    Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: February 21, 2023
    Assignees: BERGENBIO ASA, BERGEN TEKNOLOGIOVERFØRING AS
    Inventors: David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Hodneland Nilsson, Tone Sandal
  • Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus
    Patent number: 11534440
    Abstract: An Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: December 27, 2022
    Assignee: BERGENBIO ASA
    Inventors: James Bradley Lorens, Gro Gausdal
  • Anti-Axl Antagonistic Antibodies
    Publication number: 20220195054
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: November 2, 2021
    Publication date: June 23, 2022
    Applicants: BERGEN TEKNOLOGIOVERFØRING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn NILSSON, Tone SANDAL
  • Anti-Axl antagonistic antibodies
    Patent number: 11198734
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the AxI protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: December 14, 2021
    Assignees: Bergen Teknologioverføring AS, BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Nilsson, Tone Sandal
  • Anti-Axl Antagonistic Antibodies
    Publication number: 20210171643
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: June 21, 2017
    Publication date: June 10, 2021
    Applicants: BERGEN TEKNOLOGIOVERFØRING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn NILSSON, Tone SANDAL
  • COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS
    Publication number: 20200215064
    Abstract: An Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.
    Type: Application
    Filed: January 9, 2020
    Publication date: July 9, 2020
    Applicant: BerGenBio ASA
    Inventors: James Bradley LORENS, Gro GAUSDAL
  • ANTI-AXL ANTAGONISTIC ANTIBODIES
    Publication number: 20190177419
    Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: December 19, 2018
    Publication date: June 13, 2019
    Applicants: BERGEN TEKNOLOGIOVERFORING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn Hodneland NILSSON, Tone SANDAL
  • Anti-Axl antagonistic antibodies
    Patent number: 10208121
    Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 19, 2019
    Assignees: BERGEN TEKNOLOGIOVERFORING AS, BERGEBIO ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Hodneland Nilsson, Tone Sandal
  • METHODS USING AXL AS A BIOMARKER OF EPITHELIAL-TO-MESENCHYMAL TRANSITION
    Publication number: 20180246080
    Abstract: The present invention relates to the use of Axl as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject. More specifically, the invention relates to various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Axl expression and/or activity.
    Type: Application
    Filed: December 8, 2017
    Publication date: August 30, 2018
    Applicant: BERGEN TEKNOLOGIOVERFORING AS
    Inventors: James Bradley Lorens, David Robert Micklem, Lars A. Akslen
  • COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS
    Publication number: 20180153888
    Abstract: An Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.
    Type: Application
    Filed: May 27, 2016
    Publication date: June 7, 2018
    Applicant: BerGenBio ASA
    Inventors: James Bradley LORENS, Gro GAUSDAL
  • ANTI-AXL ANTAGONISTIC ANTIBODIES
    Publication number: 20170349658
    Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 7, 2017
    Applicants: BERGEN TEKNOLOGIOVERFORING AS, BERGENBIO AS
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn Hodneland NILSSON, Tone SANDAL
  • Methods using Axl as a biomarker of epithelial-to-mesenchymal transition
    Publication number: 20150212065
    Abstract: The present invention relates to the use of AxI as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject. More specifically, the invention relates to various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring AxI expression and/or activity.
    Type: Application
    Filed: August 29, 2014
    Publication date: July 30, 2015
    Inventors: James Bradley Lorens, David Robert Micklem, Lars A. Akslen
  • METHODS USING AXL AS A BIOMARKER OF EPITHELIAL-TO-MESENCHYMAL TRANSITION
    Publication number: 20120159655
    Abstract: The present invention relates to the use of AxI as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject. More specifically, the invention relates to various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring AxI expression and/or activity.
    Type: Application
    Filed: March 1, 2010
    Publication date: June 21, 2012
    Applicant: Bergen Teknologioverforing AS
    Inventors: James Bradley Lorens, David Robert Micklem, Lars A. Akslen